-
The "2020-2021 Chinese Family Standing Medicine Listed Brands" campaign is underway
Time of Update: 2021-10-11
Shanghai, September 22, 2021/PRNewswire/ - Starting in June of this year, in order to enhance the brand power of outstanding pharmaceutical companies and products, we will provide every Chinese family with a scientific and practical family-prepared medicine guide, "2020 -In 2021, China's household standing medicines will be listed on the "Brands" campaign, which is currently under application .
-
Two pharmaceutical companies "marriage" to promote the implementation of new domestic liver disease drugs
Time of Update: 2021-10-11
It is understood that in this context, Jointown and Gale will cooperate strongly to promote the implementation of new domestic liver disease drugs and help the hepatitis C elimination plan .
-
Hengrui Medicine's remazolam tosylate for injection received the notice of drug supplement application approval
Time of Update: 2021-10-11
In December 2019, the company's 36mg remazolam tosylate for injection [calculated as remazolam {C21H19BrN4O2}] was approved by the National Food and Drug Administration for routine gastroscopy sedation; it was approved for use in June 2020 Sedation of colonoscopy .
-
The Phase III clinical trial of Exploratory Pharmaceuticals Proklamide for the treatment of hospitalized patients with new crown was approved by Brazil ANVISA
Time of Update: 2021-10-11
HK, hereinafter referred to as "Kai Kuang Pharmaceutical") is pleased to announce its Procru The Phase III global multi-center clinical trial of amine for the treatment of hospitalized patients with COVID-19 was officially approved by the Brazilian drug regulatory agency ANVISA on September 22, local time .
-
The National Medical Products Administration officially accepted the listing application of Sanofi's innovative diabetes drug iGlarLixi
Time of Update: 2021-10-11
Shanghai, September 28, 2021/PRNewswire/ - Sanofi China announced that the National Medical Products Administration (NMPA) has formally accepted the company's fixed-proportion combination of basal insulin and GLP-1RA *SOLIQUA® (iGlarLixi) New drug listing application .
-
Hengrui's clinical application for 3 new drugs has been accepted
Time of Update: 2021-10-11
Famitinib Malate Capsules is a small molecule multi-target tyrosine kinase inhibitor independently developed by Hengrui.
SHR-1802 is a monoclonal antibody targeting lymphocyte activation gene 3 protein (LAG3) .
-
Release of technical guidelines for clinical evaluation of in vitro diagnostic reagents exempt from clinical trials
Time of Update: 2021-10-11
3. Basic Principles For in vitro diagnostic reagents that are exempt from clinical trials, the applicant can compare the reagents to be evaluated with the domestic marketed products, and prove that the reagents to be evaluated are substantially equivalent to the marketed products, or with reference measurement procedures/diagnostic accuracy The standard test results have good consistency .
-
CStone Pharmaceuticals announced the CS1002 (anti-CTLA-4 monoclonal antibody) and CS1003 (anti-PD-1 monoclonal antibody) phase Ib study data in patients with advanced solid tumors at the 2021 ESMO annual meeting
Time of Update: 2021-10-11
Suzhou, China, September 19, 2021/PRNewswire/ - CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focusing on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, At the 2021 European Society of Medical Oncology (ESMO) annual meeting, a phase Ib study of CS1002 (anti-CTLA-4 monoclonal antibody) and CS1003 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors was announced (CS1002- 101, NCT03523819) preliminary results (Poster ID: 981P) .
-
Chinese Women's Development Program: Reduce non-medical abortion and standardize the application of human assisted reproductive technology
Time of Update: 2021-10-11
Integrate reproductive health services into the whole process of women’s health management to ensure that women enjoy the informed and independent right to choose contraception and birth control .
-
Hengrui Medicine's "Pregabalin Sustained-Release Tablets" Approved for Listing in China
Time of Update: 2021-10-11
ArticleMedicine GuanlanToday, China's National Food and Drug Administration (NMPA) announced that the pregabalin sustained-release tablets declared by Hengrui Medicine have been approved for listing in China .
The dosage form declared by Hengrui Medicine is pregabalin sustained-release tablets .
-
Capital scrambles to lay out, digital therapy becomes "new medical outlet"
Time of Update: 2021-10-11
It is reported that in China, although digital therapy started relatively late, it has developed very rapidly.
For example, Shangyi Technology, which developed the first digital therapy app in China .
-
Xuanzhu Biotechnology introduced single-target AXL inhibitors and only one domestic company applied for clinical application
Time of Update: 2021-10-11
Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC) .
-
Strictly check pharmacies during the eleventh period!
Time of Update: 2021-10-11
On September 27, according to Hainan Daily, the Provincial Drug Administration required pharmaceutical retail companies to implement their responsibilities, strictly implement the requirements for epidemic prevention and control, monitoring and early warning, and effectively provide information lines for personnel purchasing four types of drugs for fever, cough, antiviral and antibiotics.
-
Innovent and UNION therapeutics reached a strategic cooperation to introduce next-generation PDE4 inhibitors for the treatment of inflammatory skin diseases
Time of Update: 2021-10-11
San Francisco, USA, Suzhou, China, and Hellerup, Denmark, September 28, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, p
-
Academician Joint Laboratory Guangzhou was established to accelerate the clinical transformation of medical scientific research results in the Greater Bay Area
Time of Update: 2021-10-11
Dong Jiahong, academician of the Chinese Academy of Engineering and professor of Tsinghua University, pointed out that his academician joint laboratory focuses on the innovative application of smart medical technology for hepatobiliary diseases , hoping to use smart technology to solve more hepatobiliary diseases treatment problems and technical problems, and improve Guangdong Province and the whole country.
-
The completion of the acquisition of two major multinational pharmaceutical companies is related to Novartis and Boehringer Ingelheim
Time of Update: 2021-10-11
Arctos mainly develops potential treatments for inherited retinal dystrophy (IRD) and other diseases involving loss of photoreceptors (such as AMD) .
It mainly develops new therapies around a type of intracellular antigen (atypical HLA peptide complex) newly discovered on cancer cells .
-
Bevacizumab injection, a subsidiary of Hengrui Pharmaceuticals, obtained the approval notice of drug supplement application
Time of Update: 2021-10-11
The company's bevacizumab injection (trade name: Erito) was approved for marketing in June 2021, and its indications are metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer .
In addition to Avastin and Erreto, there are currently 3 bevacizumab injections approved for marketing in China.
-
Bojian's non-opioid painkiller vixotrigine phase II trial failed
Time of Update: 2021-10-11
CompilationTom LeeA few days ago, Biogen announced that the non-opioid painkiller vixotrigine failed to achieve the expected goal of reducing the average daily pain of patients during the interim study.
-
Cinda introduces next-generation PDE4 inhibitors for 267 million yuan to treat inflammatory skin diseases
Time of Update: 2021-10-11
Article source: Medical Rubik's Cube InfoOn September 28, Innovent announced that with UNION therapeutics, UNION’s main drug candidate for the treatment of inflammatory skin diseases, orismilast, a potential best-in-class PDE4 inhibitor in clinical phase II, has reached an agreement in China (including mainland China).
-
The “cut-off” situation in the centralized procurement of Chinese patent medicines may be even worse than the self-built pharmaceutical factory is just helpless
Time of Update: 2021-10-10
If the excessive increase in raw medicinal materials causes pharmaceutical companies to "unprofitable" or lose money, this will be the main reason why manufacturers choose not to produce or "stop supply", then there is no doubt that this situation will be in the centralized procurement of Chinese patent medicines.
